NCT05673057CompletedPhase 1
A Phase 1/2a, First-in-human, Open-label, Multicenter, Dose Escalation Study of MP0533 in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Molecular Partners AG17 sites in 4 countries80 target enrollmentStarted: December 29, 2022Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Molecular Partners AG
- Enrollment
- 80
- Locations
- 17
- Primary Endpoint
- Phase 1 dose escalation: Recommended Phase 2 Dose Regimen and/or Maximum Tolerated Dose Regimen
Study Overview
Brief Summary
The purpose of this study is to evaluate the safety, tolerability, and preliminary activity of MP0533 in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Sequential
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Has signed and dated written informed consent prior to performing any study procedure, including screening
- •Diagnosis of relapsed/refractory AML or relapsed/refractory MDS/AML according to the ELN recommendation
- •Age ≥18 years old on the day of signing informed consent
- •Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 to 2
- •Anticipated life expectancy ≥ 12 weeks by investigator judgement
- •White blood count (WBC) ≤ 15G/L at day of trial drug infusion
- •Adequate renal and hepatic function
- •Is using highly effective contraception, for females of childbearing potential and for men
Exclusion Criteria
- •Mixed phenotype acute leukemia
- •Patients with favorable AML mutations according to ELN recommendation 2022 and 2024
- •Allogeneic HCT within the last 3 months and/or eligibility for standard 2nd line of targeted therapy, like gilteritinib for FLT3 mutated AML, unless this therapeutic option has already been given and proven ineffective (patient relapsed or resistant to), or contraindicated, or confounding mutations exist, or there is a lack of access to this recommended therapy.
- •More than 2 prior lines of anti-leukemic therapy
- •Active GvHD requiring immune-suppressive therapy
- •Use of immunosuppressive drugs
- •Clinical signs of AML in the central nervous system
- •Major surgery within 28 days prior to start of study medication
- •Other malignancy requiring active therapy, but adjuvant endocrine therapy is allowed
- •Any uncontrolled active infection
- •Treatment with investigational agents or agents targeting CD33, CD123 or CD70 within 4 weeks or five times the half-life of the agent, whichever is longer, prior to start of trial medication
- •Left ventricular ejection fraction of < 50% on echocardiographic exam at screening
- •History or evidence of clinically significant cardiovascular disease
- •Pulmonary disease with clinically relevant hypoxia
- •Active hepatitis
- •Concurrent enrolment in another clinical trial, unless it is an observational (non-interventional) study or it is the follow-up period of an interventional study
- •Known hypersensitivity to any of the excipients of the investigational medicinal product (IMP), i.e. finished MP0533 drug
- •Dose Expansion Group (Arm B in treatment-naïve patients only):
- •Treatment-naïve patients who are eligible to AZA+VEN as standard of care
- •Dose Escalation and Expansion Groups (Arm B only):
- •received VEN in prior treatment lines
- •received strong and/or moderate CYP3A inducers within 7 days before the initiation of AZA/VEN regimen;
- •Has consumed grapefruit, grapefruit products, Seville oranges or Starfruit within 3 days before the initiation of AZA/VEN regimen;
- •Has a malabsorption syndrome or other condition that precludes the enteral route of administration of VEN.
Arms & Interventions
Dose escalation (Part 2 - Arm B)
Experimental
- MP0533 is administered by intravenous infusion
- Azacitidine is administered by subcutaneous injection for 7 days per cycle
- Venetoclax is administered orally for 14 days per cycle
- Optional Obinutuzumab pretreatment administered
Intervention: MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) + azacitidine + venetoclax (Drug)
Dose expansion (Arm B relapsed/refractory AML)
Experimental
- MP0533 is administered by intravenous infusion
- Azacitidine is administered by subcutaneous injection for 7 days per cycle
- Venetoclax is administered orally for 14 days per cycle
- Optional Obinutuzumab pretreatment administered
Intervention: MP0533 + azacitidine + venetoclax with optional Obinutuzumab pretreatment, Arm B in treatment naïve patients (Drug)
Dose expansion (Arm B in treatment naïve patients)
Experimental
- MP0533 is administered by intravenous infusion
- Azacitidine is administered by subcutaneous injection for 7 days per cycle
- Venetoclax is administered orally for 14 days per cycle
- Optional obinutuzumab pretreatment administered
Intervention: MP0533 + azacitidine + venetoclax with optional Obinutuzumab pretreatment, Arm B relapsed/refractory AML (Drug)
Dose escalation (Part 2 - Arm A)
Experimental
- MP0533 is administered by intravenous infusion
- Obinutuzumab pretreatment administered
Intervention: MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 2-Arm A (Drug)
Dose expansion (Arm A)
Experimental
- MP0533 is administered by intravenous infusion at densified dosing schedule
- Obinutuzumab pretreatment administered
Intervention: MP0533 with Obinutuzumab pretreatment (Drug)
Dose escalation (Part 1)
Experimental
• MP0533 is administered by intravenous infusion
Intervention: MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 1 (Drug)
Outcomes
Primary Outcomes
Phase 1 dose escalation: Recommended Phase 2 Dose Regimen and/or Maximum Tolerated Dose Regimen
Time Frame: from start of treatment to end of first cycle (day 1 - 28)
Incidence of dose limiting toxicities, assessment of toxicity/safety, pharmacokinetic and efficacy parameters
Phase 2 dose extension: Overall Response Rate
Time Frame: throughout the study (on average 3 months)
Best overall response of complete remission (CR), complete remission with partial hematological recovery (CRh), complete remission with incomplete hematological recovery (CRi), morphologic leukemia-free state (MLFS) and partial remission (PR) according to the European LeukemiaNet (ELN) response criteria 2022
Secondary Outcomes
- Serum Concentration-time profiles (max. serum)(throughout the study (on average 1 year))
- Serum Concentration-time profiles (at Cmax (Tmax))(throughout the study (on average 1 year))
- Serum Concentration-time profiles (min. serum concentration)(throughout the study (on average 1 year))
- Area under the concentration-time curve (AUC)(throughout the study (on average 1 year))
- Total Clearance (CL)(throughout the study (on average 1 year))
- Volume of distribution (Vd)(throughout the study (on average 1 year))
- Half-life (t1/2)(throughout the study (on average 1 year))
- Incidence of adverse events (AEs) as a measure of safety(throughout the study (on average 1 year))
- Event free survival (EFS)(throughout the study (on average 1 year))
- Duration of response (DoR)(throughout the study (on average 1 year))
- Overall survival (OS)(throughout the study (up to 3 years))
- Transfusion-Independence (TI)(throughout the study (on average 1 year))
- Number of patients proceeding to a stem cell transplantation(throughout the study (on average 1 year))
Investigators
Study Sites (17)
Loading locations...
Similar Trials
Terminated
Phase 1
Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced MalignanciesAdvanced MalignanciesNCT02608268Novartis Pharmaceuticals252
Completed
Phase 1
A Study of DF6002 Alone and in Combination With NivolumabSolid TumorsNCT04423029Dragonfly Therapeutics170
Completed
Phase 1
Pilot Study to Assess Safety, Preliminary Efficacy and Pharmacokinetics of S.C. Pegcetacoplan (APL-2) in PNH Subjects.Paroxysmal Nocturnal HemoglobinuriaNCT02588833Apellis Pharmaceuticals, Inc.23
Completed
Phase 1
MEDI5083 Alone and in Combination With Durvalumab, Tremelimumab, and/or Docetaxel.Advanced Solid TumorsNCT03089645MedImmune LLC39
Terminated
Phase 1
First-in-Human Study of MS201408-0005A as Single Agent and in CombinationsMetastatic or Locally Advanced Unresectable Solid TumorsNCT03306420EMD Serono Research & Development Institute, Inc.15
Related News
Global CD70-Targeting Therapies Market Report 2026 Highlights Expanding Pipeline and Combination Strategies- A new market report forecasts continued expansion of the global CD70-targeting therapies pipeline across the United States, China, and Europe as candidates advance through clinical trials and regulatory review.
- Clinical development increasingly incorporates combination regimens pairing CD70 therapies with immunotherapies, epigenetic inhibitors, chemotherapy, and targeted agents to strengthen responses and address resistance.
- Leading companies including Allogene Therapeutics, Ambrx (Johnson & Johnson), Molecular Partners, and CRISPR Therapeutics are advancing differentiated programs through proprietary platforms such as allogeneic cell therapy and DARPin engineering.
- The report highlights biomarker-driven development and patient-selection strategies as key levers for more precise clinical positioning across leukemia, lymphoma, renal cell carcinoma, and autoimmune indications.last monthMolecular Partners' Radio-DARPin MP0712 Enters Clinical Trials for DLL3-Expressing Tumors- Molecular Partners' Radio-DARPin MP0712, targeting DLL3, is set to begin first-in-human trials in 2025, marking a key advancement in targeted cancer therapy.
- The collaboration between Molecular Partners and Orano Med expands to ten Radio-DARPin programs, enhancing their pipeline of targeted alpha therapies.
- Clinical data for MP0533 in relapsed/refractory AML shows improved response rates with intensified dosing, with further updates expected in 2025.last year